What is CAMP4 Therapeutics?
CAMP4 Therapeutics is at the forefront of revolutionizing drug discovery and development through its proprietary Gene Circuitry Platform. This innovative technology enables precise control over gene expression, allowing the company to identify and target druggable opportunities for a wide range of diseases. By creating tissue-specific Gene Circuitry Maps, CAMP4 Therapeutics systematically uncovers transcriptional machinery and signaling pathways, revealing numerous therapeutic targets. Their mission is to address previously undruggable diseases by deciphering the complex genetic networks that govern gene expression, aiming to make treatments possible for every disease.
How much funding has CAMP4 Therapeutics raised?
CAMP4 Therapeutics has raised a total of $175M across 3 funding rounds:
Series A
$30M
Other Financing Round
$45M
Series B
$100M
Series A (2018): $30M with participation from The Kraft Group, Polaris Partners, and Andreessen Horowitz
Other Financing Round (2021): $45M led by Polaris Partners, 5AM Ventures, Andreessen Horowitz, The Kraft Group, and Northpond Ventures
Series B (2022): $100M supported by Andreessen Horowitz, The Kraft Group, Gaingels, Northpond Ventures, Enavate Sciences, 5AM Ventures, and Polaris Partners
Key Investors in CAMP4 Therapeutics
Andreessen Horowitz
Founded in 2009, Andreessen Horowitz is a private American venture capital firm that invests in both early-stage start-ups and established growth companies. The company is headquartered in Menlo Park, California.
The Kraft Group
Founded in 1998 and headquartered in Foxborough, Massachusetts, Kraft Group is a holding company for various businesses. These businesses provide services including paper and packaging manufacturing, distribution of forest products, sports and entertainment, real estate and development, as well as private equity investing and philanthropy.
Polaris Partners
Polaris Partners Advisory is currently under construction and will be launching soon. The company aims to provide advisory services, although specific details about their products and services are not yet available. Their intended clients are not specified at this time. Further information will be available upon the company's launch.
What's next for CAMP4 Therapeutics?
The recent major strategic investment provides CAMP4 Therapeutics with significant resources to advance its platform and pipeline. This capital infusion is expected to fuel further research and development, potentially expanding its therapeutic area discovery engines and accelerating the progression of novel drug candidates toward clinical trials. The company's focus on a systematic and scalable approach to gene expression control positions it for continued expansion and leadership in the competitive biotechnology landscape, aiming to translate its platform's potential into tangible patient benefits.
See full CAMP4 Therapeutics company page
